Park Avenue Securities LLC Lowers Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Park Avenue Securities LLC trimmed its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,863 shares of the medical research company’s stock after selling 98 shares during the period. Park Avenue Securities LLC’s holdings in IQVIA were worth $759,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the stock. Private Trust Co. NA grew its stake in IQVIA by 10.7% in the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after acquiring an additional 47 shares during the period. Clear Harbor Asset Management LLC lifted its holdings in IQVIA by 1.3% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock worth $941,000 after buying an additional 50 shares in the last quarter. Pine Valley Investments Ltd Liability Co lifted its holdings in IQVIA by 0.5% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock worth $2,247,000 after buying an additional 50 shares in the last quarter. Fortitude Family Office LLC raised its stake in shares of IQVIA by 2.9% in the 3rd quarter. Fortitude Family Office LLC now owns 1,977 shares of the medical research company’s stock valued at $468,000 after purchasing an additional 56 shares in the last quarter. Finally, Huntington National Bank raised its stake in shares of IQVIA by 7.4% in the 3rd quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock valued at $192,000 after purchasing an additional 56 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently weighed in on IQV. Truist Financial dropped their price objective on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a research note on Thursday, December 12th. Morgan Stanley decreased their price objective on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Barclays cut their target price on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. The Goldman Sachs Group reduced their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, Redburn Atlantic started coverage on shares of IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 target price for the company. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $255.71.

IQVIA Stock Up 4.0 %

NYSE:IQV opened at $205.23 on Wednesday. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm has a market capitalization of $37.25 billion, a P/E ratio of 26.93, a P/E/G ratio of 2.01 and a beta of 1.48. The stock’s fifty day simple moving average is $199.69 and its 200-day simple moving average is $221.32.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.